Synklino strives to provide rapid relief as well as to improve long-term survival for transplant recipients by providing fast and safe eradication of cytomegalovirus (CMV) infections. For transplant recipients, CMV disease causes suboptimal transplantation outcome, increased morbidity, prolonged hospitalization and increased mortality.
Our drug candidate SYN002 efficiently eliminates both lytic as well as latently infected cells, and thereby potently inhibits viral replication and eradicates the virus - simply taking CMV out of the equation for the transplant recipient.
SYN002 highly potently, efficiently and selectively eliminates CMV infected cells through a proven mechanism, allowing for both stand-alone and combination therapy.
Location: Denmark, Capital Region of Denmark, Copenhagen
Employees: 1-10
Total raised: $31.97M
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | Eir Ventur... | eirventure... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.06.2022 | Series A | $31.97M | - |
Mentions in press and media 2
| Date | Title | Description | Source |
| 09.06.2022 | Synklino Closes EUR 29.8M Series A Funding | Synklino, a Copenhagen, a Denmark-based biotech company developing new drugs for the treatment of ch... | finsmes.co... |
| 02.10.2020 | Synklino Raises Seed Funding Round | Synklino ApS, a Copenhagen, Denmark-based biotech company developing first-in-class breakthrough tre... | finsmes.co... |